The invention provides an anti-
cancer sustained-
release agent co-carrying
glucocorticoid and
chemotherapeutic drugs and belongs to sustained-release injections. The anti-
cancer sustained-
release agent comprises sustained-release microspheres and a
solvent, wherein, the sustained-release microspheres comprise anti-
cancer active components and sustained-release auxiliary materials; and the
solvent is a particular
solvent containing a suspending agent. The
glucocorticoid is selected from
prednisolone,
methylprednisolone,
dexamethasone, betemethasone,
triamcinolone acetonide or
triamcinolone acetonide; the
chemotherapeutic drugs are selected from phosphoinositide 3-
kinase inhibitor,
pyrimidine analogues and the like; the sustained-release auxiliary materials are biocompatible high-polymers, such as
polylactic acid and the copolymers thereof,
polyethylene glycol, carboxyl-terminated
polylactic acid copolymers, polyfatty acid
dimer-
sebacic acid copolymers, poly(
erucic acid dimer-
sebacic acid), poly(fumaric-co-
sebacic acid), polifeprosan and the like; and the suspending agent with the
viscosity being 100cp to 3,000cp (at the temperature of 20 to 30 DEG C) is selected from
sodium carboxymethyl cellulose and the like. The anti-cancer
active components and the sustained-release microspheres can further be prepared into sustained-release implants which can effectively inhibit the growth of tumors, alleviate
edema and improve the curative effects of radiotherapy and
chemotherapy by intra-tumor or peri-tumor injection or placement.